Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,19167276,resolution factor,"Both the analytes were chromatographically separated with a resolution factor of 3.0 on a Gemini C18 (50mmx4.6mm, 5microm particle size) analytical column using 1% formic acid and methanol (50:50, v/v) as the mobile phase.",Chromatographic separation of (E)- and (Z)-isomers of entacapone and their simultaneous quantitation in human plasma by LC-ESI-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19167276/),,3.0,2873,DB00494,Entacapone
,19167276,selectivity factor (alpha),"The selectivity factor (alpha) of the column for the separation was 2.0, based on the capacity factors of 2.6 and 1.3 for (E)- and (Z)-isomers respectively.",Chromatographic separation of (E)- and (Z)-isomers of entacapone and their simultaneous quantitation in human plasma by LC-ESI-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19167276/),,2.0,2874,DB00494,Entacapone
,19167276,capacity factors,"The selectivity factor (alpha) of the column for the separation was 2.0, based on the capacity factors of 2.6 and 1.3 for (E)- and (Z)-isomers respectively.",Chromatographic separation of (E)- and (Z)-isomers of entacapone and their simultaneous quantitation in human plasma by LC-ESI-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19167276/),,2.6,2875,DB00494,Entacapone
,19167276,capacity factors,"The selectivity factor (alpha) of the column for the separation was 2.0, based on the capacity factors of 2.6 and 1.3 for (E)- and (Z)-isomers respectively.",Chromatographic separation of (E)- and (Z)-isomers of entacapone and their simultaneous quantitation in human plasma by LC-ESI-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19167276/),,1.3,2876,DB00494,Entacapone
,19167276,m,"The parent-->product ion transitions for both the isomers (m/z 306.1-->233.0) and IS (m/z 237.3-->194.2) were monitored on a triple quadrupole mass spectrometer, operating in the multiple reaction monitoring (MRM) and positive ion mode.",Chromatographic separation of (E)- and (Z)-isomers of entacapone and their simultaneous quantitation in human plasma by LC-ESI-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19167276/),,237.3,2877,DB00494,Entacapone
,19167276,process/extraction efficiency,Matrix effect was assessed by post-column analyte infusion experiment and the process/extraction efficiency found was 94.3% and 89.3% for (E)- and (Z)-isomers respectively.,Chromatographic separation of (E)- and (Z)-isomers of entacapone and their simultaneous quantitation in human plasma by LC-ESI-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19167276/),%,94.3,2878,DB00494,Entacapone
,19167276,process/extraction efficiency,Matrix effect was assessed by post-column analyte infusion experiment and the process/extraction efficiency found was 94.3% and 89.3% for (E)- and (Z)-isomers respectively.,Chromatographic separation of (E)- and (Z)-isomers of entacapone and their simultaneous quantitation in human plasma by LC-ESI-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19167276/),%,89.3,2879,DB00494,Entacapone
,8726541,duration of motor response,"The duration of motor response to levodopa increased significantly from 2.3 h to 3.2 h (i.e., by 39%) after a single dose and to 3.4 h (i.e., by 48%) after 4 weeks' medication with entacapone.","Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8726541/),h,2.3,12397,DB00494,Entacapone
,8726541,duration of motor response,"The duration of motor response to levodopa increased significantly from 2.3 h to 3.2 h (i.e., by 39%) after a single dose and to 3.4 h (i.e., by 48%) after 4 weeks' medication with entacapone.","Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8726541/),h,3.2,12398,DB00494,Entacapone
,8726541,duration of motor response,"The duration of motor response to levodopa increased significantly from 2.3 h to 3.2 h (i.e., by 39%) after a single dose and to 3.4 h (i.e., by 48%) after 4 weeks' medication with entacapone.","Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8726541/),h,3.4,12399,DB00494,Entacapone
,9754991,initial lag time,"After an initial lag time of 0.5 h, tolcapone was rapidly absorbed (peak plasma concentrations were reached within approximately 2 h) following either zero- or first-order absorption kinetics.","Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9754991/),h,0.5,17888,DB00494,Entacapone
,9754991,absolute bioavailability,The absolute bioavailability of an oral dose was approximately 60%.,"Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapy. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9754991/),%,60,17889,DB00494,Entacapone
,9754991,volume of distribution,"The volume of distribution was approximately 9 1, and the total clearance was approximately 71.h-l, resulting in a mean plasma half-life of 1.8 h.","Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapy. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9754991/),1,9,17890,DB00494,Entacapone
,9754991,total clearance,"The volume of distribution was approximately 9 1, and the total clearance was approximately 71.h-l, resulting in a mean plasma half-life of 1.8 h.","Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapy. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9754991/),h-l,71.,17891,DB00494,Entacapone
,9754991,plasma half-life,"The volume of distribution was approximately 9 1, and the total clearance was approximately 71.h-l, resulting in a mean plasma half-life of 1.8 h.","Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9754991/),h,1.8,17892,DB00494,Entacapone
,15965309,AUC,"The mean (+/-SD) plasma levodopa AUC was 39% (P = 0.0001) higher with entacapone (11,802 +/- 1454 ng/hour/mL) compared with placebo (8465 +/- 927 ng/hour/mL).",Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15965309/),[ng] / [h·ml],"11,802",34890,DB00494,Entacapone
,15965309,AUC,"The mean (+/-SD) plasma levodopa AUC was 39% (P = 0.0001) higher with entacapone (11,802 +/- 1454 ng/hour/mL) compared with placebo (8465 +/- 927 ng/hour/mL).",Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15965309/),[ng] / [h·ml],8465,34891,DB00494,Entacapone
,10901288,t1/2,"Both N-alkyl and N,N-dialkyl carbamate esters were relatively stable against chemical hydrolysis at pH 7.4 (t1/2 = 14.9-20.7 h), but hydrolyzed rapidly (t1/2 = 0.8-2.7 h) in human serum.","Synthesis and in vitro/in vivo evaluation of novel oral N-alkyl- and N,N-dialkyl-carbamate esters of entacapone. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10901288/),h,14.9-20.7,38421,DB00494,Entacapone
,10901288,t1/2,"Both N-alkyl and N,N-dialkyl carbamate esters were relatively stable against chemical hydrolysis at pH 7.4 (t1/2 = 14.9-20.7 h), but hydrolyzed rapidly (t1/2 = 0.8-2.7 h) in human serum.","Synthesis and in vitro/in vivo evaluation of novel oral N-alkyl- and N,N-dialkyl-carbamate esters of entacapone. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10901288/),h,0.8-2.7,38422,DB00494,Entacapone
exceeding,1463794,recoveries,With recoveries exceeding 75% the relative standard deviations for within-day precision were less than 11% for plasma and less than 6% for urine at the quantitation limit (10 ng ml-1) and less than 6% for both methods at higher concentrations (20-2000 ng ml-1).,"Liquid chromatographic determination of a new catechol-O-methyltransferase inhibitor, entacapone, and its Z-isomer in human plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1463794/),%,75,50354,DB00494,Entacapone
,21970858,F(a)F(g),"F(a)F(g) was calculated from pharmacokinetic parameters after intravenous and oral administration or using the portal-systemic concentration difference method, with values ranging from 0.027 (ezetimibe) to 1 (tolcapone).",Quantitative prediction of intestinal glucuronidation of drugs in rats using in vitro metabolic clearance data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21970858/),,0.027,53866,DB00494,Entacapone
,21970858,F(a)F(g),"F(a)F(g) was calculated from pharmacokinetic parameters after intravenous and oral administration or using the portal-systemic concentration difference method, with values ranging from 0.027 (ezetimibe) to 1 (tolcapone).",Quantitative prediction of intestinal glucuronidation of drugs in rats using in vitro metabolic clearance data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21970858/),,1,53867,DB00494,Entacapone
,21970858,"CL(int, UGT)","Glucuronides of model compounds were observed in the portal plasma after oral administration, with CL(int, UGT) values ranging from 57.8 (tolcapone) to 19,200 µL/min/mg (resveratrol).",Quantitative prediction of intestinal glucuronidation of drugs in rats using in vitro metabolic clearance data. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21970858/),[μl] / [mg·min],57.8,53868,DB00494,Entacapone
,21970858,"CL(int, UGT)","Glucuronides of model compounds were observed in the portal plasma after oral administration, with CL(int, UGT) values ranging from 57.8 (tolcapone) to 19,200 µL/min/mg (resveratrol).",Quantitative prediction of intestinal glucuronidation of drugs in rats using in vitro metabolic clearance data. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21970858/),[μl] / [mg·min],"19,200",53869,DB00494,Entacapone
,16285020,quantification limits,The quantification limits were 1 ng/ml for apomorphine and apocodeine and 25 ng/ml for norapomorphine.,"Development of a gas chromatographic/mass spectrometric method to quantify R(-)-apomorphine, R(-)-apocodeine and R(-)-norapomorphine in human plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16285020/),[ng] / [ml],1,55944,DB00494,Entacapone
,16285020,quantification limits,The quantification limits were 1 ng/ml for apomorphine and apocodeine and 25 ng/ml for norapomorphine.,"Development of a gas chromatographic/mass spectrometric method to quantify R(-)-apomorphine, R(-)-apocodeine and R(-)-norapomorphine in human plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16285020/),[ng] / [ml],25,55945,DB00494,Entacapone
,16485914,elimination half-life (t(1/2)),The elimination half-life (t(1/2)) of levodopa from plasma (in combination with a decarboxylase inhibitor) of about 1.5 hours becomes more influential as the disease progresses.,Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16485914/),h,1.5,61864,DB00494,Entacapone
,33093598,apparent clearances (CL/F),"The final model was a one compartment model with a high fixed absorption rate constant, and a first order elimination, with estimated apparent clearances (CL/F), of 27.9 L/h/70 kg for LCIG versus 17.5 L/h/70 kg for LECIG, and apparent volume of distribution of 74.4 L/70 kg.",Population pharmacokinetics of levodopa gel infusion in Parkinson's disease: effects of entacapone infusion and genetic polymorphism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33093598/),[l] / [70·h·kg],27.9,64634,DB00494,Entacapone
,33093598,apparent clearances (CL/F),"The final model was a one compartment model with a high fixed absorption rate constant, and a first order elimination, with estimated apparent clearances (CL/F), of 27.9 L/h/70 kg for LCIG versus 17.5 L/h/70 kg for LECIG, and apparent volume of distribution of 74.4 L/70 kg.",Population pharmacokinetics of levodopa gel infusion in Parkinson's disease: effects of entacapone infusion and genetic polymorphism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33093598/),[l] / [70·h·kg],17.5,64635,DB00494,Entacapone
,33093598,apparent volume of distribution,"The final model was a one compartment model with a high fixed absorption rate constant, and a first order elimination, with estimated apparent clearances (CL/F), of 27.9 L/h/70 kg for LCIG versus 17.5 L/h/70 kg for LECIG, and apparent volume of distribution of 74.4 L/70 kg.",Population pharmacokinetics of levodopa gel infusion in Parkinson's disease: effects of entacapone infusion and genetic polymorphism. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33093598/),[l] / [70·kg],74.4,64636,DB00494,Entacapone
,9695725,C50,"The second was C50(carbidopa) = 951 ng/ml; C50(benserazide) = 1238 ng/ml, where C50 is the steady-state plasma concentration of levodopa eliciting half of maximum attainable effect, and carbidopa and benserazide are the dopa decarboxylase inhibitors given in the study.",Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9695725/),[ng] / [ml],951,69384,DB00494,Entacapone
,9695725,C50,"The second was C50(carbidopa) = 951 ng/ml; C50(benserazide) = 1238 ng/ml, where C50 is the steady-state plasma concentration of levodopa eliciting half of maximum attainable effect, and carbidopa and benserazide are the dopa decarboxylase inhibitors given in the study.",Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9695725/),[ng] / [ml],1238,69385,DB00494,Entacapone
,25855267,Bioavailability,"Bioavailability of LD from ER CD-LD was 83.5%, 78.3%, and 58.8% relative to IR CD-LD, CR CD-LD, and CD-LD-entacapone, respectively.","Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet(®)), sustained-release carbidopa-levodopa (Sinemet(®) CR), and carbidopa-levodopa-entacapone (Stalevo(®)). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25855267/),%,83.5,105136,DB00494,Entacapone
,25855267,Bioavailability,"Bioavailability of LD from ER CD-LD was 83.5%, 78.3%, and 58.8% relative to IR CD-LD, CR CD-LD, and CD-LD-entacapone, respectively.","Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet(®)), sustained-release carbidopa-levodopa (Sinemet(®) CR), and carbidopa-levodopa-entacapone (Stalevo(®)). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25855267/),%,78.3,105137,DB00494,Entacapone
,25855267,Bioavailability,"Bioavailability of LD from ER CD-LD was 83.5%, 78.3%, and 58.8% relative to IR CD-LD, CR CD-LD, and CD-LD-entacapone, respectively.","Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet(®)), sustained-release carbidopa-levodopa (Sinemet(®) CR), and carbidopa-levodopa-entacapone (Stalevo(®)). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25855267/),%,58.8,105138,DB00494,Entacapone
,22762460,FI,"FI for dose 2-5 was on average 1.26 for levodopa in LC-5, and 2.23 for dose 1-2 of LCE.",Frequent administration of levodopa/carbidopa microtablets vs levodopa/carbidopa/entacapone in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22762460/),,1.26,105533,DB00494,Entacapone
,22762460,FI,"FI for dose 2-5 was on average 1.26 for levodopa in LC-5, and 2.23 for dose 1-2 of LCE.",Frequent administration of levodopa/carbidopa microtablets vs levodopa/carbidopa/entacapone in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22762460/),,2.23,105534,DB00494,Entacapone
,11294372,volume of the central compartment (Vc),"The volume of the central compartment (Vc) and the volume of distribution at steady state (Vss) were 0.08+/-0.03 l/kg and 0.27+/-0.10 l/kg, respectively.","Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294372/),[l] / [kg],0.08,113234,DB00494,Entacapone
,11294372,volume of distribution at steady state (Vss),"The volume of the central compartment (Vc) and the volume of distribution at steady state (Vss) were 0.08+/-0.03 l/kg and 0.27+/-0.10 l/kg, respectively.","Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294372/),[l] / [kg],0.27,113235,DB00494,Entacapone
,11294372,Total plasma clearance (Cltot),Total plasma clearance (Cltot) averaged 11.7+/-1.9 ml/min kg(-1).,"Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294372/),[min·ml] / [kg],11.7,113236,DB00494,Entacapone
,11294372,half-lives,"The half-lives for the distribution phase and for the rapid and terminal elimination phases (t1/2alpha, t1/2beta and t1/2gamma) were 0.05+/-0.01 h, 0.38+/-0.16 h and 2.40+/-1.70 h, respectively.","Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294372/),h,0.05,113237,DB00494,Entacapone
,11294372,half-lives,"The half-lives for the distribution phase and for the rapid and terminal elimination phases (t1/2alpha, t1/2beta and t1/2gamma) were 0.05+/-0.01 h, 0.38+/-0.16 h and 2.40+/-1.70 h, respectively.","Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294372/),h,0.38,113238,DB00494,Entacapone
,11294372,t1/2alpha,"The half-lives for the distribution phase and for the rapid and terminal elimination phases (t1/2alpha, t1/2beta and t1/2gamma) were 0.05+/-0.01 h, 0.38+/-0.16 h and 2.40+/-1.70 h, respectively.","Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294372/),h,0.05,113239,DB00494,Entacapone
,11294372,t1/2beta,"The half-lives for the distribution phase and for the rapid and terminal elimination phases (t1/2alpha, t1/2beta and t1/2gamma) were 0.05+/-0.01 h, 0.38+/-0.16 h and 2.40+/-1.70 h, respectively.","Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294372/),h,0.05,113240,DB00494,Entacapone
,11294372,t1/2beta,"The half-lives for the distribution phase and for the rapid and terminal elimination phases (t1/2alpha, t1/2beta and t1/2gamma) were 0.05+/-0.01 h, 0.38+/-0.16 h and 2.40+/-1.70 h, respectively.","Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294372/),h,0.38,113241,DB00494,Entacapone
,11294372,t1/2gamma,"The half-lives for the distribution phase and for the rapid and terminal elimination phases (t1/2alpha, t1/2beta and t1/2gamma) were 0.05+/-0.01 h, 0.38+/-0.16 h and 2.40+/-1.70 h, respectively.","Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294372/),h,2.40,113242,DB00494,Entacapone
,11294372,total,"The terminal elimination phase accounted for only 9% of the total area under the plasma concentration-time curve (AUC), which was 409 +/- 98 ng h/ml after the i.v. dose.","Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294372/),[h·ng] / [ml],409,113243,DB00494,Entacapone
,11294372,area under the plasma concentration-time curve (AUC),"The terminal elimination phase accounted for only 9% of the total area under the plasma concentration-time curve (AUC), which was 409 +/- 98 ng h/ml after the i.v. dose.","Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294372/),[h·ng] / [ml],409,113244,DB00494,Entacapone
,11294372,time to reach the peak concentration (tmax),"Oral entacapone was absorbed rapidly with a time to reach the peak concentration (tmax) of 0.9+/-0.4 h, a maximum concentration (Cmax) of 457+/-334 ng/ml and an AUC of 497+/-118 ng h/ml.","Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294372/),h,0.9,113245,DB00494,Entacapone
,11294372,maximum concentration (Cmax),"Oral entacapone was absorbed rapidly with a time to reach the peak concentration (tmax) of 0.9+/-0.4 h, a maximum concentration (Cmax) of 457+/-334 ng/ml and an AUC of 497+/-118 ng h/ml.","Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294372/),[ng] / [ml],457,113246,DB00494,Entacapone
,11294372,AUC,"Oral entacapone was absorbed rapidly with a time to reach the peak concentration (tmax) of 0.9+/-0.4 h, a maximum concentration (Cmax) of 457+/-334 ng/ml and an AUC of 497+/-118 ng h/ml.","Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294372/),[h·ng] / [ml],497,113247,DB00494,Entacapone
,11294372,recovery,"During the 48 h after dosing, the recovery of free and conjugated unchanged 13C-entacapone in urine was 38.1+/-7.2% of the i.v. dose and the recovery of free and conjugated unchanged entacapone 13.3+/-3.9% of the oral dose.","Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294372/),%,38.1,113248,DB00494,Entacapone
,11294372,recovery,"During the 48 h after dosing, the recovery of free and conjugated unchanged 13C-entacapone in urine was 38.1+/-7.2% of the i.v. dose and the recovery of free and conjugated unchanged entacapone 13.3+/-3.9% of the oral dose.","Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294372/),%,13.3,113249,DB00494,Entacapone
,11294372,bioavailability,The bioavailability of oral entacapone was 25% based on the AUC values and 35% based on urinary excretion.,"Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294372/),%,25,113250,DB00494,Entacapone
,11294372,bioavailability,The bioavailability of oral entacapone was 25% based on the AUC values and 35% based on urinary excretion.,"Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294372/),%,35,113251,DB00494,Entacapone
,12538800,elimination half-life (t(1/2 beta)),"After intravenous administration (3 mg/kg), the elimination half-life (t(1/2 beta)) of entacapone (0.8 h) was clearly shorter than that of tolcapone (2.9 h).",Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12538800/),h,0.8,129875,DB00494,Entacapone
,12538800,elimination half-life (t(1/2 beta)),"After intravenous administration (3 mg/kg), the elimination half-life (t(1/2 beta)) of entacapone (0.8 h) was clearly shorter than that of tolcapone (2.9 h).",Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12538800/),h,2.9,129876,DB00494,Entacapone
,12538800,K(i),"Entacapone and tolcapone inhibited equally rat liver COMT in vitro with K(i) values of 10.7 and 10.0 nM, respectively.",Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12538800/),nM,10.7,129877,DB00494,Entacapone
,12538800,K(i),"Entacapone and tolcapone inhibited equally rat liver COMT in vitro with K(i) values of 10.7 and 10.0 nM, respectively.",Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12538800/),nM,10.0,129878,DB00494,Entacapone
,19412946,area-under-the-concentration-curve,"PK analysis revealed the anticipated near-equivalent mean L-dopa area-under-the-concentration-curve values (639,490 ng min/mL for two doses of CLE, and 662,577 for CL-CR, P = 0.86).",Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19412946/),[min·ng] / [ml],"639,490",150783,DB00494,Entacapone
,19412946,area-under-the-concentration-curve,"PK analysis revealed the anticipated near-equivalent mean L-dopa area-under-the-concentration-curve values (639,490 ng min/mL for two doses of CLE, and 662,577 for CL-CR, P = 0.86).",Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19412946/),,"662,577",150784,DB00494,Entacapone
,19412946,maximal concentration,"The mean maximal concentration for the first CLE dose was 1,926 +/- 760 ng/mL and for CL-CR, 1,840 +/- 889 (P = 0.33).",Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19412946/),[ng] / [ml],"1,926",150785,DB00494,Entacapone
,19412946,CL-CR,"The mean maximal concentration for the first CLE dose was 1,926 +/- 760 ng/mL and for CL-CR, 1,840 +/- 889 (P = 0.33).",Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19412946/),,"1,840",150786,DB00494,Entacapone
,19412946,CL-CR,"During the PK studies, the mean time that L-dopa concentration was > or =1,000 ng/mL for CLE was 291 +/- 88 minutes and for CL-CR, 306 +/- 86 (P = 0.33).",Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19412946/),,306,150787,DB00494,Entacapone
,19412946,percent-time,"The mean percent-time in ""off"" state was 18% for CLE and 28% for CL-CR (P = 0.017), ""on state without dyskinesia"" was 64% for CLE and 65% for CL-CR (P = 0.803), and ""on state with nontroublesome dyskinesia"" was 18% for CLE and 7% for CL-CR (P = 0.03).",Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19412946/),%,18,150788,DB00494,Entacapone
,19412946,percent-time,"The mean percent-time in ""off"" state was 18% for CLE and 28% for CL-CR (P = 0.017), ""on state without dyskinesia"" was 64% for CLE and 65% for CL-CR (P = 0.803), and ""on state with nontroublesome dyskinesia"" was 18% for CLE and 7% for CL-CR (P = 0.03).",Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19412946/),%,28,150789,DB00494,Entacapone
,19412946,percent-time,"The mean percent-time in ""off"" state was 18% for CLE and 28% for CL-CR (P = 0.017), ""on state without dyskinesia"" was 64% for CLE and 65% for CL-CR (P = 0.803), and ""on state with nontroublesome dyskinesia"" was 18% for CLE and 7% for CL-CR (P = 0.03).",Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19412946/),%,64,150790,DB00494,Entacapone
,19412946,percent-time,"The mean percent-time in ""off"" state was 18% for CLE and 28% for CL-CR (P = 0.017), ""on state without dyskinesia"" was 64% for CLE and 65% for CL-CR (P = 0.803), and ""on state with nontroublesome dyskinesia"" was 18% for CLE and 7% for CL-CR (P = 0.03).",Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19412946/),%,65,150791,DB00494,Entacapone
,19412946,percent-time,"The mean percent-time in ""off"" state was 18% for CLE and 28% for CL-CR (P = 0.017), ""on state without dyskinesia"" was 64% for CLE and 65% for CL-CR (P = 0.803), and ""on state with nontroublesome dyskinesia"" was 18% for CLE and 7% for CL-CR (P = 0.03).",Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19412946/),%,7,150792,DB00494,Entacapone
,9358559,Apparent K(m),Apparent K(m) values for the nitrocatechols varied greatly depending on substitution pattern being comparable with 4-nitrophenol (0.11 mM) only in the case of 4-nitrocatechol (0.19 mM).,"Glucuronidation of entacapone, nitecapone, tolcapone, and some other nitrocatechols by rat liver microsomes. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9358559/),mM,0.11,172183,DB00494,Entacapone
,9358559,Apparent K(m),Apparent K(m) values for the nitrocatechols varied greatly depending on substitution pattern being comparable with 4-nitrophenol (0.11 mM) only in the case of 4-nitrocatechol (0.19 mM).,"Glucuronidation of entacapone, nitecapone, tolcapone, and some other nitrocatechols by rat liver microsomes. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9358559/),mM,0.19,172184,DB00494,Entacapone
,9358559,Vmax,"Simple nitrocatechols showed two-fold Vmax values compared with 4-nitrophenol (68.6 nmol min-1 mg-1), while all disubstituted catechols exhibited much lower glucuronidation rate.","Glucuronidation of entacapone, nitecapone, tolcapone, and some other nitrocatechols by rat liver microsomes. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9358559/),[nM] / [mg·min],68.6,172185,DB00494,Entacapone
,7791104,elimination half-life,"In addition, the elimination half-life (2.66 hr) and volume of distribution by area of L-dopa in blood plasma and its AUC and t1/2 in muscle ECF (1.80 hr) were enhanced substantially.",The effect of carbidopa and entacapone pretreatment on the L-dopa pharmacokinetics and metabolism in blood plasma and skeletal muscle in beagle dog: an in vivo microdialysis study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7791104/),h,2.66,177336,DB00494,Entacapone
,7791104,volume of distribution by area,"In addition, the elimination half-life (2.66 hr) and volume of distribution by area of L-dopa in blood plasma and its AUC and t1/2 in muscle ECF (1.80 hr) were enhanced substantially.",The effect of carbidopa and entacapone pretreatment on the L-dopa pharmacokinetics and metabolism in blood plasma and skeletal muscle in beagle dog: an in vivo microdialysis study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7791104/),h,1.80,177337,DB00494,Entacapone
,7791104,AUC,"In addition, the elimination half-life (2.66 hr) and volume of distribution by area of L-dopa in blood plasma and its AUC and t1/2 in muscle ECF (1.80 hr) were enhanced substantially.",The effect of carbidopa and entacapone pretreatment on the L-dopa pharmacokinetics and metabolism in blood plasma and skeletal muscle in beagle dog: an in vivo microdialysis study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7791104/),h,1.80,177338,DB00494,Entacapone
,7791104,t1/2,"In addition, the elimination half-life (2.66 hr) and volume of distribution by area of L-dopa in blood plasma and its AUC and t1/2 in muscle ECF (1.80 hr) were enhanced substantially.",The effect of carbidopa and entacapone pretreatment on the L-dopa pharmacokinetics and metabolism in blood plasma and skeletal muscle in beagle dog: an in vivo microdialysis study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7791104/),h,1.80,177339,DB00494,Entacapone
,8039535,maximum inhibition,Oral entacapone dose-dependently decreased the activity of S-COMT in RBCs with a maximum inhibition of 82% after the highest dose (800 mg).,Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8039535/),%,82,187366,DB00494,Entacapone
,8039535,tmax,"Oral absorption of entacapone was fast, with a tmax ranging from 0.4 to 0.9 h, depending on the dose.",Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8039535/),h,0.4 to 0.9,187367,DB00494,Entacapone
,8039535,Systemic availability,Systemic availability of entacapone varied between 30 and 46%.,Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8039535/),%,30 and 46,187368,DB00494,Entacapone
,8039535,half-life,Entacapone was rapidly eliminated by metabolism with a half-life of 0.27-0.30 h after oral doses of 5 to 50 mg.,Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8039535/),h,0.27-0.30,187369,DB00494,Entacapone
,8039535,t1/2 alpha,After doses from 100 to 800 mg the disposition was best described by two phases with a t1/2 alpha of 0.27-0.37 h and t1/2 beta of 1.59-3.44 h.,Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8039535/),h,0.27-0.37,187370,DB00494,Entacapone
,8039535,t1/2 beta,After doses from 100 to 800 mg the disposition was best described by two phases with a t1/2 alpha of 0.27-0.37 h and t1/2 beta of 1.59-3.44 h.,Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8039535/),h,1.59-3.44,187371,DB00494,Entacapone
,10492060,t1/2,"The mean t1/2 values of entacapone were 1.3 h and 1.8 h during the first and sixth days, respectively; the difference was not significant.",Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492060/),h,1.3,190584,DB00494,Entacapone
,10492060,t1/2,"The mean t1/2 values of entacapone were 1.3 h and 1.8 h during the first and sixth days, respectively; the difference was not significant.",Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492060/),h,1.8,190585,DB00494,Entacapone
,10492060,Cmax,"There were no between-day differences in Cmax, t1/2 (2.4 h on days 1-2 and 2.3 h on days 6-7) or AUC of levodopa, whereas tmax occurred at 0.8 h on day 1 and at 1.2 h on day 6 (P = 0.03).",Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492060/),h,2.4,190586,DB00494,Entacapone
,10492060,t1/2,"There were no between-day differences in Cmax, t1/2 (2.4 h on days 1-2 and 2.3 h on days 6-7) or AUC of levodopa, whereas tmax occurred at 0.8 h on day 1 and at 1.2 h on day 6 (P = 0.03).",Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492060/),h,2.4,190587,DB00494,Entacapone
,10492060,t1/2,"There were no between-day differences in Cmax, t1/2 (2.4 h on days 1-2 and 2.3 h on days 6-7) or AUC of levodopa, whereas tmax occurred at 0.8 h on day 1 and at 1.2 h on day 6 (P = 0.03).",Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492060/),h,2.3,190588,DB00494,Entacapone
,10492060,tmax,"There were no between-day differences in Cmax, t1/2 (2.4 h on days 1-2 and 2.3 h on days 6-7) or AUC of levodopa, whereas tmax occurred at 0.8 h on day 1 and at 1.2 h on day 6 (P = 0.03).",Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492060/),h,0.8,190589,DB00494,Entacapone
,10492060,tmax,"There were no between-day differences in Cmax, t1/2 (2.4 h on days 1-2 and 2.3 h on days 6-7) or AUC of levodopa, whereas tmax occurred at 0.8 h on day 1 and at 1.2 h on day 6 (P = 0.03).",Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492060/),h,1.2,190590,DB00494,Entacapone
,20220040,peak increase,"The peak increase in plasma NE (0.57 ± 0.11 nmol/L) averaged less than 1/15,000 th that in L-DOPS and less than 1/35th that in DHPG+DHMA.",Effects of carbidopa and entacapone on the metabolic fate of the norepinephrine prodrug L-DOPS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20220040/),[nM] / [l],0.57,202503,DB00494,Entacapone
,14718682,bioavailability,"In switching patients who are receiving levodopa/carbidopa controlled-release (CR), it should be noted that the bioavailability of levodopa from levodopa/carbidopa CR is approximately 70-75% that of levodopa/carbidopa IR products, including Stalevo.",Levodopa/carbidopa/entacapone (Stalevo). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14718682/),%,70-75,236483,DB00494,Entacapone
,18303486,ON time,"After the levodopa test doses, ON time significantly increased 29 minutes with 75 mg nebicapone, 45 minutes with 150 mg nebicapone, and 16 minutes with 200 mg entacapone.","Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18303486/),min,29,266411,DB00494,Entacapone
,18303486,ON time,"After the levodopa test doses, ON time significantly increased 29 minutes with 75 mg nebicapone, 45 minutes with 150 mg nebicapone, and 16 minutes with 200 mg entacapone.","Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18303486/),min,45,266412,DB00494,Entacapone
,18303486,ON time,"After the levodopa test doses, ON time significantly increased 29 minutes with 75 mg nebicapone, 45 minutes with 150 mg nebicapone, and 16 minutes with 200 mg entacapone.","Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18303486/),min,16,266413,DB00494,Entacapone
,8112370,area under the plasma concentration curve (AUC),"Entacapone significantly increased the mean area under the plasma concentration curve (AUC) of levodopa by 46%, from 3620 to 5280 h.ng.ml-1 and prolonged its elimination half-life (t1/2el) from 1.5 h to 2.0 h.","Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112370/),[h·ng] / [ml],3620,266437,DB00494,Entacapone
,8112370,area under the plasma concentration curve (AUC),"Entacapone significantly increased the mean area under the plasma concentration curve (AUC) of levodopa by 46%, from 3620 to 5280 h.ng.ml-1 and prolonged its elimination half-life (t1/2el) from 1.5 h to 2.0 h.","Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112370/),[h·ng] / [ml],52,266438,DB00494,Entacapone
,8112370,elimination half-life (t1/2el),"Entacapone significantly increased the mean area under the plasma concentration curve (AUC) of levodopa by 46%, from 3620 to 5280 h.ng.ml-1 and prolonged its elimination half-life (t1/2el) from 1.5 h to 2.0 h.","Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112370/),h,1.5,266439,DB00494,Entacapone
,8112370,elimination half-life (t1/2el),"Entacapone significantly increased the mean area under the plasma concentration curve (AUC) of levodopa by 46%, from 3620 to 5280 h.ng.ml-1 and prolonged its elimination half-life (t1/2el) from 1.5 h to 2.0 h.","Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112370/),h,2.0,266440,DB00494,Entacapone
,8112370,AUC,"The mean AUC of 3,4-dihydroxyphenylacetic acid (DOPAC), the monoamine oxidase-dependent metabolite of levodopa, was significantly increased from 122 to 343 h.micrograms.","Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112370/),h·μg,122,266441,DB00494,Entacapone
,8112370,AUC,"The mean AUC of 3,4-dihydroxyphenylacetic acid (DOPAC), the monoamine oxidase-dependent metabolite of levodopa, was significantly increased from 122 to 343 h.micrograms.","Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112370/),h·μg,343,266442,DB00494,Entacapone
,8112370,AUC,"A small decrease in the AUC of homovanillic acid (HVA), the COMT dependent metabolite of levodopa, was observed (from 455 to 303 h.ng.ml-1).","Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112370/),[h·ng] / [ml],455,266443,DB00494,Entacapone
,8112370,AUC,"A small decrease in the AUC of homovanillic acid (HVA), the COMT dependent metabolite of levodopa, was observed (from 455 to 303 h.ng.ml-1).","Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112370/),[h·ng] / [ml],303,266444,DB00494,Entacapone
,7648772,maximal increase,"The maximal increase in heart rate during isoproterenol infusion after entacapone administration (40 +/- 11 beats/min, mean +/- SD) was statistically greater (p = 0.0496) than after placebo administration (27 +/- 7 beats/min).",The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7648772/),[beats] / [min],40,270060,DB00494,Entacapone
,7648772,maximal increase,"The maximal increase in heart rate during isoproterenol infusion after entacapone administration (40 +/- 11 beats/min, mean +/- SD) was statistically greater (p = 0.0496) than after placebo administration (27 +/- 7 beats/min).",The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7648772/),[beats] / [min],27,270061,DB00494,Entacapone
,7648772,heart rate,The increase in heart rate during epinephrine infusion was 25 +/- 13 beats/min after entacapone administration and 14 +/- 9 beats/min after placebo administration (p = 0.127).,The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7648772/),[beats] / [min],25,270062,DB00494,Entacapone
,7648772,heart rate,The increase in heart rate during epinephrine infusion was 25 +/- 13 beats/min after entacapone administration and 14 +/- 9 beats/min after placebo administration (p = 0.127).,The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7648772/),[beats] / [min],14,270063,DB00494,Entacapone
